Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer

Expert Opinion on Investigational Drugs

Volumn 24, Issue 3, 2015, Pages 421-431

  Geuna, Elena ^a   Milani, Andrea ^a   Martinello, Rossella ^a,b   Aversa, Caterina ^a,b   Valabrega, Giorgio ^b   Scaltriti, Maurizio ^c   Montemurro, Filippo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Buparlisib; Chemotherapy; Endocrine therapy; HER2 directed therapy; Mammalian target of rapamycin; Phosphatidylinositol 3 kinase

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BUPARLISIB; HER 2 INHIBITOR; HORMONE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; MORPHOLINE DERIVATIVE; NVP-BKM120;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION;

EID: 84923034490     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1008132     Document Type: Article

References (72)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30
2. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490(7418):61-70
3. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 2013;24(9):2206-23
4. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005;123(4):541-6
5. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82
6. Early Breast Cancer Trialists' Collaborative G. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378(9793):771-84
7. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28(3):509-18
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84
9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
10. Kuss JT, Muss HB, Hoen H, Case LD. Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Treat 1997;42(3):265-74
11. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 2004;9 Suppl 3:20-6
12. Montemurro F, Scaltriti M. Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol 2014;232(2):219-29
13. Ghayad SE, Vendrell JA, Ben Larbi S, et al. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 2010;126(2):545-62
14. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9(9):631-43
15. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149(2):274-93
16. Miller TW, Rexer BN, Garrett JT, et al. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011;13(6):224
17. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6(2):117-27
18. Loibl S, von Minckwitz G, Schneeweiss A, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to antihuman epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014;32(29):3212-20
19. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007;26(9):1338-45
20. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8(8):627-44
21. Baselga J, Cortes J, Im SA, et al. Biomarker analyses in CLEOPATRA: A Phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 2014;32(33):3753-61
22. Sabine VS, Crozier C, Brookes CL, et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 2014;20(32):2951-8
23. Markman B, Tao JJ, Scaltriti M. PI3K pathway inhibitors: better not left alone. Curr Pharm Des 2013;19(5):895-906
24. Beeram M, Tan QT, Tekmal RR, et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007;18(8):1323-8
25. Schiff R, Massarweh SA, Shou J, et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10(1 Pt 2):331S-6S
26. Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120(7):2406-13
27. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68(3):826-33
28. Liu H, Zang C, Schefe JH, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Anticancer Res 2011;31(9):2713-22
29. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9
30. Andre F, O'Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet Oncol 2014;15(6):580-91
31. Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012;11(2):317-28
32. Voliva Cf PS, Burger M, Nagel T, et al. Biological characterization of NVPBKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials. Cancer Res 2010;70:4498-8; Abstract 4498
33. Burger MT, Pecchi S, Wagman A, et al. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS medicinal chemistry letters 2011;2(10):774-9
34. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011;13(2):R21
35. Miller TW, Balko JM, Fox EM, et al. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011;1(4):338-51
36. Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012;2(11):1048-63
37. Ibrahim YH, Garcia-Garcia C, Serra V, et al. PI3K inhibition impairs BRCA1/ 2 expression and sensitizes BRCAproficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012;2(11):1036-47
38. Graupera M, Guillermet-Guibert J, Foukas LC, et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008;453(7195):662-6
39. Schnell C SF, Allegrini P, O'Reilly T, et al. NVP-BKM120, a pan class I PI3K inhibitor impairs microvascular permeability and tumor growth as detected by DCE-MRI and IFP measurements via radio-telemetry: Comparison with NVP-BEZ235. Cancer Res 2010;70:4472-2; abstract 4472
40. Brachmann SM, Kleylein-Sohn J, Gaulis S, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther 2012;11(8):1747-57
41. Nanni P, Nicoletti G, Palladini A, et al. Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/-mice and treatment with PI3K inhibitor. PLoS ONE 2012;7(6):e39626
42. Ackermann TF, Hortnagl H, Wolfer DP, et al. Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala. Cell Physiol Biochem 2008;22(5-6):735-44
43. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30(3):282-90
44. Ando Y, Inada-Inoue M, Mitsuma A, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci 2014;105(3):347-53
45. Saura C, Bendell J, Jerusalem G, et al. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clin Cancer Res 2014;20(7):1935-45
46. Mayer IA, Abramson VG, Isakoff SJ, et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2014;32(12):1202-9
47. Azaro A, Rodon J, Vansteenkiste J, et al. Hyperglycemia in patients treated with the pan-PI3K inhibitor buparlisib (BKM120): characterization, management, and assessment for pharmacodynamics. Eur J Cancer 2013;49(Suppl 2): S186, abstract 884
48. Rodon J, Brana I, Siu LL, et al. Phase I dose-escalation and-expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014;32(4):670-81
49. Zambrano C SM, Machiels JP, Hess D, et al. Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). J Clin Oncol 2014;32(5s Suppl):abstract 627
50. Dees Ec MP, Snavely A, Noe J, et al. Phase I dose escalation clinical trial of the PI3K inhibitor BKM120 and capecitabine (C) in metastatic breast cancer (MBC). The 36th San Antonio Breast Cancer Symposium 2014:abstract PD1-16-13
51. Ma CX WJ, Luo J, Naughton M, et al. A phase I study of BKM120 and fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer. The 36th San Antonio Breast Cancer Symposium 2014:abstract PD1-4
52. Lopez-Knowles E, O'Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancerspecific mortality. Int J Cancer 2010;126(5):1121-31
53. Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 2011;16(4):404-14
54. Chakrabarty A, Bhola NE, Sutton C, et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res 2013;73(3):1190-200
55. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68(19):8022-30
56. Ibrahim YH, García-García C, Serra V, et al. PI3K inhibition impairs BRCA1/ 2 expression and sensitizes BRCAproficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012;2(11):1036-47
57. Matulonis WG, Birrer MJ, Westin S, et al. Phase I study of oral BKM120 and oral olaparib for high grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC). J Clin Oncol 2014;32(5s Suppl):abstract 2510
58. Chu Q MA, Schuler M, De Braud FGM, et al. Dose-escalation study of sonedigib (LDE225) plus buparlisib (BKM120) in patients with advanced solid tumours. ESMO presentation 2014
59. Riobo NA, Lu K, Ai X, et al. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci USA 2006;103(12):4505-10
60. Brechbiel J, Miller-Moslin K, Adjei AA. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat Rev 2014;40(6):750-9
61. Martin M BN, Shtivelband M, Chan A, et al. Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without PI3K pathway activation: A phase II, randomized, double-blind, placebocontrolled study-BELLE-4. SABCS 2013. Cancer Res 2013;73(24 Suppl; abstract nr OT2-6-07
62. Loi S LS, Di Cosimo S, Nekljudova V, et al. Phase II, randomized, parallelcohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer-NeoPHOEBE. SABCS 2013. Cancer Res 2013;73(24 Suppl; abstract nr OT2-6-08
63. Mayer I FP, Gnant M, Campone M, et al. Phase II, randomized, placebocontrolled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2-, PIK3CA mutant or wild-type, breast cancer (BC). J Clin Oncol 2014;32(5s Suppl):abstract TPS655
64. Goncalves A IN, Campone M, Dieras V, et al. PIKHER2: A phase Ib/II study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2-positive, PI3K-activated, trastuzumab-resistant advanced breast cancer. ASCO poster 2013. J Clin Oncol 2013;31(Suppl):abstract TPS663
65. Foukas LC, Claret M, Pearce W, et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006;441(7091):366-70
66. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6(9):729-34
67. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66(3):1500-8
68. Tabernero J, Rojo F, Calvo E, et al. Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26(10):1603-10
69. Chandarlapaty S, Sawai A, Scaltriti M, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011;19(1):58-71
70. Serra V, Scaltriti M, Prudkin L, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011;30(22):2547-57
71. Elkabets M, Vora S, Juric D, et al. mTORC1 inhibition is required for sensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med 2013;5(196):196ra99
72. Available from: http://www.clinicaltrials. gov [Last accessed 28 October 2014]